QDQunli Ding

Qunli Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qunli Ding has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Lun Guo

    Department of Respiratory Medicine, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, People’s Republic of China

    6 shared publications
  • Qipan Zhang

    Department of Infectious Diseases, the First Affiliated Hospital of Ningbo University, Ningbo, People’s Republic of China

    6 shared publications
  • Chengna Lv

    Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, China

    5 shared publications
  • Xuxiang Song

    The Second Hospital of Jiaxing: The Second Affiliated Hospital of Jiaxing University

    5 shared publications
  • Yun Zhang

    Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, China

    5 shared publications
  • Hongying Ma

    Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315000, China

    4 shared publications

Latest Publications

  • Prophylactic Hemostatic Treatment to Control Iatrogenic Bleeding During Endobronchial Biopsy (PROTECT Study)

    by Bei Li, Li He, Wei Wu, Min Ji, Wen Zhang, Lina Wang, Tanushree Kochar, Fang Yue, Aijun Zhang, Yijun Ge, et al.


  • Open Access

    Serum Tumor Marker Profiles in Interstitial Lung Diseases: Implications for Differential Diagnosis and Disease Severity Assessment

    by Yingying Du, Xuxiang Song, Qunli Ding

    Background: Interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated ILD (CTD-ILD), share similar features that complicate diagnosis. Tumor markers are often elevated in ILD, yet their diagnostic utility remains unclear. Methods: This retrospective study included ILD patients hospitalized between 2018 and 2025. Serum levels of alpha-fetoprotein, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199, CA125, CA153, neuron-specific enolase (NSE), and cytokeratin 19 fragment (CYFRA 21-1) were analyzed. Arterial blood gases and erythrocyte sedimentation rates (ESRs) were also collected. Statistical analyses involved the Kruskal–Wallis test, Dunn’s post hoc test, Spearman’s correlation, logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: CEA, CA199, and CA125 levels varied significantly among ILD subtypes (all p < 0.05). NSE differed among CTD-ILD subgroups (p = 0.0409). In IPF, CEA and NSE correlated inversely with PaO? (r = -0.1556, p = 0.0380; r = -0.2205, p = 0.0031). In CTD-ILD, NSE correlated negatively with PaCO? (r = -0.1811, p = 0.016), and CYFRA 21-1 with PaO? (r = -0.1999, p = 0.0078). A diagnostic model incorporating CEA, CA199, sex, age, smoking, PaO?, and ESR differentiated IPF from CTD-ILD with an AUC of 0.833 (95% CI: 0.790–0.876), showing 73.6% sensitivity and 82.4% specificity at a cutoff of 0.569, outperforming single markers. Conclusion: CEA, CA199, and CA125 aid in distinguishing ILD subtypes, while CEA, NSE, and CYFRA 21-1 correlate with impaired gas exchange. The combined clinical and biomarker model demonstrated superior performance in discriminating IPF from CTD-ILD, highlighting its clinical potential.

  • Open Access

    Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo

    by Di Wu, Yapeng Hou, Wei Fan, Yingying Du, Qunli Ding

    Background: Idiopathic inflammatory myopathies (IIMs) are characterized by chronic muscle inflammation and often involve multiple organ systems. Despite treatment, a large number of patients still experience relapse or disease progression. Currently, there is a lack of high-quality studies specifically focusing on recurrence, and early identification of patients at high risk of recurrence remains challenging.Methods: This retrospective study included patients with idiopathic inflammatory myopathy complicated by interstitial lung disease who were hospitalized in the First Affiliated Hospital of Ningbo University from January 2018 to December 2024. All included individuals were followed up for at least 12 months. The diagnosis of idiopathic inflammatory myopathies and interstitial lung disease (ILD) was based on relevant criteria. A wide range of clinical and laboratory data were collected. Significant variables were screened through univariate and multivariate regression analyses, and risk models for predicting recurrence at 1, 2, and 3 years were constructed, with subsequent evaluation of the models’ performance.Results: Among the 93 included patients, the recurrence rate was 23.7%, with a median time to recurrence of 38 months. Approximately 26.1% of recurrences were attributed to drug discontinuation or adjustment. Multivariate analysis suggested that positive anti-RO52 antibody, positive anti-PL7 antibody, elevated white blood cell count, elevated ALT, and elevated LDH were positively correlated with the risk of recurrence. The area under the ROC curve (AUC) for recurrence prediction was: 1-year: 1.00 (95% CI: 1.00–1.00), 2-year: 0.91 (95% CI: 0.75–1.08), 3-year: 0.92 (95% CI: 0.78–1.05).Conclusion: Based on baseline clinical and laboratory indicators, this study developed a tool with good predictive ability for IIM-ILD recurrence, which can accurately assess individual recurrence risk and assist in early clinical decision-making.Trial registration number: IRB No:2025092RS.


  • Open Access

    Prognostic significance of acute exacerbations and usual interstitial pneumonia in fibrotic interstitial lung disease

    by Yun Zhang, Zekai Cen, Qunli Ding, Yanan Ying, Chengna Lv, Tingting Wu

    Fibrotic interstitial lung disease (FILD) is a general term that includes many diseases that manifest as pulmonary fibrosis and are often progressive and associated with high morbidity. However, there are limited data regarding the frequency and prognosis of FILD patients other than those with idiopathic pulmonary fibrosis (IPF). The purpose of this study was to investigate the clinical characteristics and early prognostic risk factors for FILD. This study retrospectively reviewed the data of patients who were diagnosed with FILD between April 2011 and September 2022 in our centre. Ultimately, 194 patients diagnosed with non-IPF fibrotic ILD were screened in our study. Baseline clinical information, pulmonary function tests, and chest images were collected and analysed. Connective tissue disease-related interstitial lung disease (CTD-ILD) (60.3%) was the most common subgroup of FILD and associated with longer survival than the other types of FILD. The age at diagnosis of ILD (64.4 ± 13.5 vs. 70.0 ± 11.6 years, P = 0.001) and the proportion of males, smokers and acute exacerbations (AEs) (13.5% vs. 27.5%, P = 0.026) were significantly higher in the UIP group than in the NSIP group. The Kaplan‒Meier survival analysis showed that the IPF group (HR 1.97, 95% CI 1.05–3.70, P = 0.011) had a worse survival rate than the FILD group, and landmark analyses showed that the survival of FILD patients with the UIP pattern (HR 3.07 95% CI 1.37–6.86 P = 0.006) was significantly shorter than that of FILD patients with the NSIP pattern 48 months after ILD diagnosis. In the multivariate Cox analysis, AEs of ILD (HR 4.17 95% CI 2.24–7.75 P < 0.001) and combined with lung cancer (HR 3.12 95% CI 1.27–7.65 P = 0.013) remained as significant factors that were independently associated with shorter survival. CTD-ILD is the most common subgroup of FILD in our study, and the prognosis is better than that of other types of FILD. Patients with the UIP pattern tend to be older and have a higher proportion of AEs. The prognosis is worse than that of patients with the NSIP pattern in the later stage. AEs and combined with lung cancer are independent risk factors for the prognosis of FILD patients, and more attention should be given to such patients.


  • Open Access

    The Role and Clinical Significance of Vitamin D in Chronic Obstructive Pulmonary Disease

    by Mengqing Sun, Yang Qian, Chenting Cai, Jiaqian Zhang, Ruonan Qi, Hongying Ma, Qunli Ding, Shanshan Wang, Dan Lv

    Vitamin D is well known for its role in bones, but it also has a variety of extra-skeletal effects. Vitamin D deficiency is becoming a global health problem. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the world, resulting in an enormous medical and economic burden. Accumulating evidence indicates a high prevalence of vitamin D deficiency in patients with COPD, which has emerged as a significant modulator of disease progression. This comprehensive review systematically examines the multifactorial etiology of vitamin D deficiency in COPD, encompassing insufficient sunlight exposure, malnutrition, smoking, comorbidities, and chronic inflammatory states. Clinical observational studies have demonstrated significant associations between vitamin D deficiency and increased exacerbation frequency, accelerated lung function decline, and elevated mortality risk. Mechanistically, we elucidate the pleiotropic effects of vitamin D in COPD pathogenesis, including its anti-inflammatory activity, suppression of oxidative stress, modulation of innate and adaptive immunity, inhibition of hepcidin, and reduction in pulmonary infection risk. Building on current evidence, we critically evaluate the clinical efficacy of various vitamin D supplementation strategies. This review aims to provide clinicians with an evidence-based framework for incorporating vitamin D assessment and supplementation into comprehensive COPD management while also identifying key directions for future research.


  • Open Access

    Interleukin −39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy

    by Xuxiang Song, Qipan Zhang, Tiantian Cen, Wei Fan, Weili Chen, Lun Guo, Yingying Du, Chengna Lv, Pan Tang, Zhaoxing Dong, et al.

    Objective: This study aimed to assess Interleukin-39 (IL-39) levels in various types of pleural effusion (PE), explore IL-39’s diagnostic value in tuberculous pleurisy, analyze its correlation with other PE and tuberculosis indicators, and confirm the involvement of IL-39 in tuberculosis infection and the resulting inflammatory response. Methods: This study enrolled 113 patients with PE caused by different etiologies: 20 with transudative effusion, 39 with malignant pleural effusion (MPE), 15 with uncomplicated parapneumonic effusion (UPPE), and 39 with tuberculous pleural effusion (TPE). Enzyme-linked immunosorbent assay (ELISA) was used to measure IL-39, interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) levels in the pleural fluid (PF) of each group. Adenosine deaminase (ADA) activity was determined using the colorimetric method. Results: IL-39 concentration was notably higher in the TPE compared to others. The IL-39 demonstrated an AUC of 0.944, with a cut-off value of 39.8 pg/mL, sensitivity of 94.9%, and specificity of 79.7% in distinguishing between the TPE and non-TPE. In discriminating between the TPE and MPE, the AUC for IL-39 was 0.941, with a cut-off value of 39.3 pg/mL, sensitivity of 94.9%, and specificity of 79.5%. For differentiating the TPE and UPPE, IL-39 yielded an AUC of 0.885, with a cut-off value of 235.0 pg/mL, sensitivity of 66.7%, and specificity of 100.0%. Moreover, based on these findings, multivariable diagnostic model and the rapid combination of IL-39 with other tuberculosis biomarkers (such as IFN-γ, TNF-α, and ADA) significantly enhanced the diagnostic and differential diagnostic performance for TPE. Additionally, IL-39, IFN-γ, TNF-α, and ADA levels in PF were positively correlated with each other. Conclusion: IL-39 demonstrated good diagnostic and differential diagnostic value for TPE. Furthermore, the multivariate diagnostic model, as well as the joint detection of IL-39 with other tuberculosis biomarkers, can further increased the sensitivity or specificity. Additionally, IL-39 exhibited positive correlations with other tuberculosis biomarkers, suggesting its potential involvement in tuberculosis infection and the inflammatory response it may induce.


  • Open Access

    Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort

    by Yanan Ying, Tingting Wu, Long Wang, Yun Zhang, Yiming Yu, Zaichun Deng, Qunli Ding

    Introduction: The diagnosis of amyopathic dermatomyositis with interstitial lung disease (ADM-ILD) is challenging due to the lack of typical skin features and overlapping syndromes. We aimed to determine the characteristics and prognosis of patients with ADM-ILD to further guide their clinical management. Methods: A retrospective cohort study comprising 190 Chinese patients diagnosed with interstitial lung disease (ILD) was conducted. Patients were stratified into four groups using the Sontheimer criteria and predominant high-resolution computed tomography (HRCT) patterns. Demographic features, clinical presentation, laboratory parameters, duration of ILD, and follow-up data were analysed. Results: There were significant differences in the clinical parameters among the 190 patients with ILD in the amyopathic dermatomyositis (ADM, n = 69) and control (n = 121) groups. The ADM with nonspecific interstitial pneumonia (NSIP) group (n = 46) presented increased haemoglobin (125.93 ± 12.91 g/L, p = 0.005), creatine kinase-MB (15.19 ± 8.58 U/L, p < 0.001), and partial pressure of oxygen (93.08 ± 26.20 mmHg, p = 0.003) levels and decreased β2-microglobulin (2.61 ± 1.21 mg/L, p = 0.039) levels compared to the control-NSIP group (n = 92). The ADM with organizing pneumonia (OP) group (n = 23) had a greater percentage of females (7/16, p = 0.023) and higher alanine aminotransferase (30.30 ± 20.67 U/L, p = 0.039) and aspartate aminotransferase (53.35 ± 65.86 U/L, p = 0.003) levels than the control-OP group (n = 29). Both the ADM-NSIP and OP groups presented elevated lactate dehydrogenase (LDH) levels (290.61 ± 86.49 U/L, p = 0.009; 317.35 ± 181.32 U/L, p = 0.003, respectively) and increased anti-nuclear antibody (ANA) positivity rates (82.61%, p = 0.01; 73.91%, p < 0.001, respectively). Notably, 81.26% of patients with ADM-NSIP/OP had LDH levels above normal. The serum LDH levels could be used to distinguish patients with ADM-NSIP/OP (sensitivity: 73.91%, specificity: 82.64%). Survival was shorter among patients with ADM-OP than among control patients (p = 0.002). Cox multivariate analysis revealed that age (p = 0.002), smoking status (p = 0.011), anti-melanoma differentiation-associated gene 5 (MDA5) antibody (p = 0.017), and white blood cell count (p = 0.004) were independent predictors of shorter survival. Conclusions: Elevated serum LDH levels in patients predominantly presenting with NSIP or OP patterns may indicate the presence of ADM-ILD. The identified prognostic factors underscore the importance of early detection and personalized management strategies for optimizing outcomes in patients with ADM-ILD.


  • Open Access

    The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer

    by Heng Ma, Tingting Wu, Qipan Zhang, Qunli Ding

    This study assessed the diagnosis, staging and treatment guidance of lung cancer (LC) based on seven tumor-associated autoantibodies (TAAbs) —p53, PGP9.5, SOX2, GBU4-5, MAGE A1, CAGE, and GAGE7. ELISA was used to determine the TAAb serum levels in 433 patients diagnosed with LC (161 surgical patients) and 76 patients with benign lung disease (16 surgical patients). The statistical characteristic of the TAAbs was compared among patients with different clinicopathological features. Pre- to postoperative changes in TAAb levels were analyzed to determine their value of LC. Among all patients, the positive rate of the seven TAAbs was 23.4%, sensitivity was 26.3%, accuracy was 36.3%, specificity was 93.4%, positive predictive value was 95.8%, and negative predictive value was 18.2%; the positive rate for the LC group (26.3%) was significantly higher than that for the benign group (6.6%; P < 0.001). Significant differences in the positive rate of the seven autoantibodies according to age (P < 0.001), smoking history (P = 0.009) and clinical LC stage (P < 0.001) were found. Smoking was positively associated with the positive of TAAbs (Τ = 0.118, P = 0.008). The positive rates of the seven TAAbs for squamous carcinoma (54.5%), other pathological types (44.4%) and poorly differentiated LC (57.1%) were significantly higher than those for the other types. The positive rate of GBU4-5 was highest among all TAAbs, and the SOX2 level in stage III-IV patients was much higher than that in other stages. For patients undergoing surgery, compared with the preoperative levels, the postoperative levels of the 7 markers, particularly p53 (P = 0.027), PGP9.5 (P = 0.007), GAGE7 (P = 0.014), and GBU4-5 (P = 0.002), were significantly different in the malignant group, especially in stage I-II patients, while no clear pre- to postoperative difference was observed in the benign group. When the seven TAAbs was positive, it was very helpful for the diagnosis of LC. The 7 TAAbs was valuable for staging and guiding treatment of LC in surgical patients.


  • The diagnostic value of interleukin-36 cytokines in pleural effusions of varying etiologies

    by Xuxiang Song, Lun Guo, Qipan Zhang, Weili Chen, Wei Fan, Chengna Lv, Pan Tang, Zhaoxing Dong, Xudeng Ye, Qunli Ding